Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 392

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 392
---
 Kellerhals, Hirschgässlein 11, 4051 Basel, Switzerland |     | Dormant            |     | -a) (b |

Notes:

| (a) | Wholly owned subsidiary of Biodexa Limited. |

| (b) | PharMida AG became dormant in January 2016. |

| F-52 |

| 13 | Trade and other receivables |

| Schedule of trade and other receivables |     |            |     |            |     |            |
|                                         |     | 2023 £’000 |     | 2022 £’000 |     | 2021 £’000 |
| Trade receivables                       |     |          – |     |        329 |     |         33 |
| Prepayments                             |     |        355 |     |        376 |     |        607 |
| Other receivables                       |     |        282 |     |        301 |     |        394 |
| Total trade and other receivables       |     |        637 |     |      1,006 |     |      1,034 |
| Less: non-current portion               |     |          – |     |          – |     |          – |
| Current portion                         |     |        637 |     |      1,006 |     |      1,034 |

The Group has applied
the practical expedient permitted by IFRS 15 to not disclose the transaction price allocated to performance obligations unsatisfied (or
partially unsatisfied) as of the end of the reporting period as contracts typically have an original expected duration of a year or less.

Book values approximate
to fair value at 31 December 2023, 2022 and 2021.

Expected Credit Loss

Given
the short-term nature of the Group’s trade receivables and accrued income, which are mainly due from large national or multinational
companies, the Group's assessment of expected credit losses includes provisions for specific clients and receivables where the contractual
cash flow is deemed at risk. Considerations include the current economic environment along with historical and forward-looking information.
No assumptions or estimating techniques are applied in considering these. Additional provisions are made based on the assessment of recoverability
of aged receivables over one year where sufficient evidence of recoverability is not evident.

Trade
and other receivables contained one impaired asset in 2022, as detailed below,